An illustration · invented records · this source is real
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx
Andre F, Ismaila N, Henry NL, Somerfield MR, et al. (2019). Journal of Clinical Oncology. PubMed 31150316 · DOI 10.1200/JCO.19.00945 · PubMed record
What kind of source: Professional society guideline, focused update after TAILORx. Where it sits in the summary: Established. Back to the summary
What it says, in plain language
ASCO’s reading of TAILORx into practice: what the score ranges mean for node-negative disease, by age.
Source access: this note uses the published abstract, linked above. The full article was not available for this review and is not included in the folder.
The exact words we relied on
“For patients with hormone receptor-positive, axillary node-negative breast cancer whose tumors have Oncotype DX recurrence scores of less than 26, there is little to no benefit from chemotherapy, especially for patients older than age 50 years. Clinicians may recommend endocrine therapy alone for women older than age 50 years.” — PMID:31150316, Abstract, Updated Recommendations
“Patients with recurrence scores greater than 30 should be considered candidates for chemoendocrine therapy. Based on informal consensus, the panel recommends that oncologists may offer chemoendocrine therapy to these patients with recurrence scores of 26 to 30.” — PMID:31150316, Abstract, Updated Recommendations
How these quotes were checked
Follow the passage links above to the included paper or public source record.
Abstract only. The quotes above come from the paper’s published abstract as held in the PubMed record. They were checked by exact string match against the PubMed record cached on 2026-09-08. This note is limited to the abstract; the full article was not read.
Limits of this source
Superseded in part by the 2022 update, which adds node-positive disease. Abstract only.
Review
Reviewed by Sarah Kiselycznyk · September 10, 2026. Review scope and verification method: How we researched this.